PNEUMOVAX 23 25 MCG / 0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 25 MCG / 0.5 ML · DIN 02436442 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is PNEUMOVAX 23?
PNEUMOVAX 23 25 MCG / 0.5 ML contains PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 25 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02436442, held by MERCK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 20-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02436442 |
|---|---|
| Brand name | PNEUMOVAX 23 |
| Generic / active ingredient | PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 25 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 25 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 25 MCG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AL01 PNEUMOCOCCUS, PURIFIED POLYSACCHARIDES ANTIGEN |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 20-Aug-2025 |
| Original market date | 2021-04-07 00:00:00 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.